Astellas Pharma Ltd in agreement with the Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a statement about Veoza (fezolinetant), highlighting a risk of drug-induced liver injury and new recommendations on the monitoring of liver function before and during treatment.